Osimertinib mesylate salt form · mesylate · Parent Osimertinib mesylate · Synonyms: AZD-9291 mesylate | Mereletinib mesylate

Osimertinib mesylate is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor.

For research use only. Not for human or veterinary use.

Target EGFR

Research area Cancer

Purity >99% Stock Inquire

Data Sheet SDS COA

Osimertinib mesylate structure

CAS No.: 1421373-66-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 g	USD 598.00	BP-01886A-100g	In stock	Get quote

Custom Size Bulk Inquiry

Description

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].

Identifiers

SMILES: CS(O)(=O)=O.COC1=C(NC2=NC(=CC=N2)C2=CN(C)C3=CC=CC=C23)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
InChIKey: FUKSNUHSJBTCFJ-UHFFFAOYSA-N

Specifications

MW (average): 595.7130
Formula: C₂₉H₃₇N₇O₅S
CAS No.: 1421373-66-1
Physical state: Solid
Color: White to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃, sealed storage, away from moisture; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.

[2]. [2]Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17(4):740-750.

Same target

Search EGFR

Same research area

Search Cancer